The estimated Net Worth of Joris Wilms is at least $480 Tausend dollars as of 26 August 2024. Mr. Wilms owns over 5,000 units of Y-Mabs Therapeutics Inc stock worth over $406,062 and over the last 6 years he sold YMAB stock worth over $73,450. In addition, he makes $0 as Chief Operating Officer und Senior Vice President at Y-Mabs Therapeutics Inc.
Joris has made over 1 trades of the Y-Mabs Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of YMAB stock worth $73,450 on 26 August 2024.
The largest trade he's ever made was selling 5,000 units of Y-Mabs Therapeutics Inc stock on 26 August 2024 worth over $73,450. On average, Joris trades about 556 units every 0 days since 2018. As of 26 August 2024 he still owns at least 30,600 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Mr. Wilms stock trades at the bottom of the page.
Joris Wiel Jan Wilms is Chief Operating Officer, Senior Vice President of the company. Mr. Wilms has served as our Senior Vice President and Chief Operating Officer since November 2017. Mr. Wilms joined our Company in July 2016 as Vice President and Head of Clinical Operations and has extensive industry experience in clinical development, primarily within oncology and hematology indications. Mr. Wilms was at KLIFO A/S ("KLIFO") from 2010 to 2016, where he served as Vice President—Clinical Trial Services and Pharmacovigilance Services, and at Genmab from 2004 to 2010, where he served as Associate Director of Clinical Development from 2008 to 2010. At KLIFO and Genmab, he was responsible for overseeing several first-in-human studies and pivotal clinical trials, leading to the approval of two monoclonal antibody-based products. Mr. Wilms received his M.Sc. in Pharmacy from the University of Groningen in The Netherlands.
Joris Wilms is 46, he's been the Chief Operating Officer und Senior Vice President of Y-Mabs Therapeutics Inc since 2017. There are 16 older and 3 younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.
Joris's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK, NY, 10169.
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad und Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include: